xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

256

International consensus statement on rhinosinusitis

1 – Low inflammation, controls 2 – IL-17A, IFN-y, TNF α 3 – IL-2, 4, 6, 17A, IFN- γ , TNF α 4 – IL-2, IL-10, TNF

3 – Th2 dominant; high IL-5, 6, 9, 10, 13, eotaxin, IFN- γ 8 total;

5 – IL-8, macrophages 6 – IL-5, 6, eosinophils, neutrophils, macrophages 7–AERD

8 – IL-6, 8, neutrophils, T cells, B-cells, macrophages

4 – Th2 dominant; high IL-2, IL-3, IL-4, IL-17 5 – Low IL-5, high IL-1b

6 – High IL-4, 5, 6, 7, 8, 12, 13, 17-A, 21, TNFa

Study Year LOE Study Design Study Groups Main Biomarkers Endotypes Turner 46 2018 4 Case-control 90 patients, 17 controls in theU.S. Mucus: IL-1 β , IL-2, IL-3. IL-4. IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-17A, Eotaxin, IFN-y, TNF α , RANTES 6 total; Low inflammation: 1 – High IL-5 2 – Low IL-1b and IL-12 High inflammation:

Tissue: CD3 + T cells, CD20 + B

cells, CD68 + macrophages,

IL-6, IL-8, IL-10, IL-13, IL-17A, IFN- γ , andTNF

plasma cells, eosinophils,

neutrophils, IL-2, IL-4, IL-5,

Hoggard 50 2018 4 Case-control 93 patients, 17 controls in New Zealand

TABLE V-3 (Continued)